IMVT Jul 2022 7.500 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 7.50 |
| Expiry date | 2022-07-15 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 733 |
- Zacks
Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development
Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.
- Zacks
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.
- GlobeNewswire
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022
Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expected for both in the first half of calendar year 2025Immunovant estimates annual addressable U.S. TED population for a new mechanism of action to be 8,000-18,000 patientsImmunovant on track to initiate pivotal Phase 3 clinical trial of batoclimab in myasthenia gravis (MG), by the end of June 2022Cash balance of $494
